Olatunji Alese
Emory University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Olatunji Alese as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04191421 · Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerEmory University · completed · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- Ph2NCT03983993 · Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal CancerEmory University · active not recruiting · Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable · principal investigator
- Ph1NCT03373188 · VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerEmory University · completed · Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · fiscal years 2009 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:03 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.JAMA Oncol · 2020375 citationsRCR 15.2
- Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.J Immunother Cancer · 202349 citationsRCR 3.8
- 44 citationsRCR 9.1
- 43 citationsRCR 5.0
- 28 citationsRCR 1.2
- Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.Cell Rep Med · 202525 citationsRCR 5.8
- Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.J Clin Oncol · 202417 citationsRCR 1.8
- A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.Clin Cancer Res · 202013 citationsRCR 0.5
- XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.Oncoimmunology · 202512 citationsRCR 2.9
- Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.J Hepatol · 202611 citationsRCR 5.5